Track topics on Twitter Track topics that are important to you
With Celltrion still awaiting the U.S. FDA's approval of its proposed biosimilar of Remicade (infliximab), its marketing subsidiary Celltrion Healthcare is aiming to launch a planned initial public of...
Celltrion announced that it plans to market Remsima, a biosimilar version of Johnson & Johnson's and Merck & Co.'s rheumatoid -More-
Celltrion, which sells a cheap version of a top-selling rheumatoid arthritis drug in Europe, is now targeting the U.S., the world’s biggest pharmaceutical market.
Contradictory requests from the US FDA on the statistical analysis of Remsima are one of many regulatory hurdles facing biosimilar developers, according to Celltrion.
Celltrion’s Remsima campaign rolled into the US this week with another presentation of data showing that the Remicade (Infliximab) biosimilar is equivalent to the reference drug.
Celltrion has emphasised the savings Remsima ((inflizimab) could offer at a conference in Spain as partner Napp Pharmaceuticals prepares to extend the roll out of the Remicade biosimilar to the UK.
Korean biopharma company Celltrion Healthcare has presented data on the clinical experience of patients…
Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease. Date: ...